SGLT2is offers real-world renal protective benefits over DPP4i in T2D

Key clinical point: In patients with type 2 diabetes (T2D), the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) vs. dipeptidyl peptidase-4 inhibitors (DPP4i) was associated with a lower risk for end-stage renal disease (ESRD) and acute renal failure (ARF) and a slower decline in the estimated glomerular filtration rate (eGFR).

Major finding: Over a median follow-up of 3.8 years, the use of SGLT2i vs. DPP4i was associated with a significantly lower risk for ESRD (hazard ratio [HR] 0.51; P < .001) and ARF (HR 0.59; P < .001) and a significantly slower decline in eGFR (−0.060 vs. −0.625 mL/min/1.73m²  per year; P_interaction < .001).

Study details: This retrospective cohort study propensity score matched 6333 patients with T2D receiving an SGLT2i with 25,332 of those receiving a DPP4i.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Au PCM et al. Association between SGLT20iInhibitors vs DPP4 inhibitors and renal outcomes among patients with type 2 diabetes. J Clin Endocrinol Metab. 2022 (Mar 18). Doi:  10.1210/clinem/dgac164

Key clinical point: In patients with type 2 diabetes (T2D), the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) vs. dipeptidyl peptidase-4 inhibitors (DPP4i) was associated with a lower risk for end-stage renal disease (ESRD) and acute renal failure (ARF) and a slower decline in the estimated glomerular filtration rate (eGFR).

Major finding: Over a median follow-up of 3.8 years, the use of SGLT2i vs. DPP4i was associated with a significantly lower risk for ESRD (hazard ratio [HR] 0.51; P < .001) and ARF (HR 0.59; P < .001) and a significantly slower decline in eGFR (−0.060 vs. −0.625 mL/min/1.73m²  per year; P_interaction < .001).

Study details: This retrospective cohort study propensity score matched 6333 patients with T2D receiving an SGLT2i with 25,332 of those receiving a DPP4i.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Au PCM et al. Association between SGLT20iInhibitors vs DPP4 inhibitors and renal outcomes among patients with type 2 diabetes. J Clin Endocrinol Metab. 2022 (Mar 18). Doi:  10.1210/clinem/dgac164

Key clinical point: In patients with type 2 diabetes (T2D), the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) vs. dipeptidyl peptidase-4 inhibitors (DPP4i) was associated with a lower risk for end-stage renal disease (ESRD) and acute renal failure (ARF) and a slower decline in the estimated glomerular filtration rate (eGFR).

Major finding: Over a median follow-up of 3.8 years, the use of SGLT2i vs. DPP4i was associated with a significantly lower risk for ESRD (hazard ratio [HR] 0.51; P < .001) and ARF (HR 0.59; P < .001) and a significantly slower decline in eGFR (−0.060 vs. −0.625 mL/min/1.73m²  per year; P_interaction < .001).

Study details: This retrospective cohort study propensity score matched 6333 patients with T2D receiving an SGLT2i with 25,332 of those receiving a DPP4i.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Au PCM et al. Association between SGLT20iInhibitors vs DPP4 inhibitors and renal outcomes among patients with type 2 diabetes. J Clin Endocrinol Metab. 2022 (Mar 18). Doi:  10.1210/clinem/dgac164